We have shown that a bacteriophage lambda genetic screen system may be useful in predicting the activity and phenotype of HIV-1 protease in the course of viral infection and antiretroviral therapy. This simple and rapid genetic screening system has been used here to characterize HIV-1 proteases encoding single primary resistance substitutions. Except for proteases with amino acid changes at positions 46 and 84, proteases containing single-resistance substitutions displayed a lower catalytic efficiency than the WT enzyme. Single mutants could be identified by their efficiency, demonstrating that modest differences in protease activity can be monitored with this simple assay. Overall, drug susceptibility could be reduced by introduction of single mutations. However, high-level protease inhibitor (PI) resistance was only achieved by multiple mutated proteases. The small but reproducible increase in resistance displayed by single mutants also demonstrated the ability of this genetic screen system for detecting minor reductions in drug susceptibility. These results show that the bacteriophage lambda genetic screen system used here is a useful tool in the analysis of specific contribution of mutations in the HIV protease-coding region or in specific cleavage sites that affect the process of PI resistance. © 2002 Elsevier Science (USA) 
INTRODUCTION
Protease inhibitors (PI) are extensively used in combination with reverse transcriptase inhibitors in the treatment of human immunodeficiency virus type 1 (HIV-1) infected patients (Carpenter et al., 2000) . The clinical use of combination regimens (including at least three antiretroviral drugs) has reduced HIV-1-related morbidity and mortality (Palella et al., 1998) . However, when therapies fail to achieve a complete and sustained suppression of virus replication, drug-resistant virus mutants can emerge . PI resistance appears to be the consequence of a multifactorial process, which includes protease gene mutations as well as changes outside of its DNA-coding region (Bally et al., 2000; Cote et al., 2001; Doyon et al., 1996; Kaufmann et al., 2001; Koch et al., 2001; La Seta Catamancio et al., 2001; Mammano et al., 1998; Shafer et al., 1999; Zennou et al., 1998; Zhang et al., 1997) . A progressive accumulation of mutations in the protease-coding region has been observed either in HIV-1 protease derived from treated patients or in tissue-culture replication studies (Cabana et al., 1999; Carrillo et al., 1998; Condra et al., 1995; Hertogs et al., 2000; Kaufmann et al., 2001; Mammano et al., 1998; Molla et al., 1996; Shafer et al., 1998; Vaillancourt et al., 1999; Zhang et al., 1997) . In both cases, a complex mutational pattern has been observed. Amino acid changes in the protease-coding region categorized as primary resistance mutations basically affect enzyme susceptibility to drug binding (Maschera et al., 1996; Schock et al., 1996) . Primary resistance substitutions are the first to appear and are considered to be critical for drug resistance. Secondary resistance substitutions also contribute to overall drug resistance but they may have less direct effect on inhibitor binding. Secondary mutations develop later and improve enzyme function (Boden and Markowitz, 1998; Hirsch et al., 2000; Mammano et al., 2000) .
Although cross-resistance can be detected among the current PIs, every PI seems to be associated with certain primary resistance mutations. Amino acid substitutions V82A and I84V emerged in patients treated with ritonavir (RTV) and after several ex vivo serial passages of HIV-1 laboratory-adapted strains (Boden and Markowitz, 1998; Eastman et al., 1998; Markowitz et al., 1995; Molla et al., 1996; Schmit et al., 1996) . Saquinavir (SQV) predominantly selects the amino acid changes L90M and G48V that are accompanied by other mutations (Boden and Markowitz, 1998; Craig et al., 1998; Ives et al., 1997; Jacobsen et al., 1996; Roberts, 1995; Vaillancourt et al., 1999) . For indinavir (IDV) primary substitutions M46L and V82A may not be the first mutations, but they are selected in most patient isolates in combination with other mutations (Boden and Markowitz, 1998; Condra et al., 1995 Condra et al., , 1996 Zhang et al., 1997) . Ex vivo serial passages of HIV-1 in the presence of nelfinavir (NFV) resulted in selection of variants containing the D30N substitution, which is also the main primary resistance mutation se-lected in patients treated with NFV-containing regimens (Atkinson et al., 2000; Boden and Markowitz, 1998; Patick et al., 1996 Patick et al., , 1998 . Finally, amprenavir-containing treatments have been recently shown to select the substitution I50V, which has not been previously reported with other PIs (Boden and Markowitz, 1998) . It seems that there are signature mutations for the specific PI resistance. However, common mutations that confer crossresistance can also be selected. Thus, NFV can select the substitution L90M in addition to D30N and amprenavir can select the substitution I84V in addition to I50V .
Recently, we have adapted a new genetic assay system (Sices and Kristie, 1998) , based on the bacteriophage lambda, for the characterization of the activity and phenotype of HIV-1 proteases . This genetic screen system is based on the bacteriophage lambda regulatory circuit where the viral repressor cI is specifically cleaved to initiate lysogenic to lytic switch. Introduction of an HIV-1 protease in a wild-type (WT) phage will cleavage a mutant cI repressor containing a specific HIV-1 protease cleavage site, allowing the phage to go into the lytic replication cycle. Here, we report the characterization of the activity of seven HIV-1 single mutant proteases encoding one primary resistance mutation: D30N, M46L, G48V, I50V, V82A, I84V, or L90M. We also assessed how these substitutions affect PI susceptibility. This genetic screen system provides a simple alternative approach to the evaluation of the catalytic activity and phenotype of HIV-1 protease variants.
RESULTS

Influence of primary resistance mutations on HIV-1 protease activity
We previously showed that the catalytic activity of HIV-1 protease can be monitored by using a simple bacteriophage-based genetic screen system . Specific cleavage of the HIV-1 p17/p24 (SQNYPIVQ) cleavage site located inside cI lambda repressor allowed the characterization of the HIV-1 protease catalytic activity Sices and Kristie, 1998) . Several studies have demonstrated that viral variants encoding multiple PI resistance mutations show a variable reduction in drug-free virus infectivity (Bleiber et al., 2001; Mammano et al., 1998 Mammano et al., , 2000 Martinez-Picado et al., 1999 Nijhuis et al., 1999; Stoddart et al., 2001; Zennou et al., 1998) . In the present study we established the impact of single primary resistance substitutions in the catalytic efficiency of HIV-1 protease by using the abovementioned genetic screen system. Phages containing the HIV-1 protease single mutants D30N, M46L, G48V, I50V, V82A, I84V, and L90M were constructed (-HIVp). Escherichia coli cells expressing the HIV-1 cI repressor construct were then infected with recombinant phages encoding the different mutant pro-tease enzymes. After two cycles of selective growth (see Materials and Methods), the resulting phage was titered ( Fig. 1) . A phage encoding the protease from the laboratory strain HXB2 (-HIVpHXB2) was used as positive control and designated as the catalytic activity of WT HIV-1 protease. Similarly, a phage encoding an inverted HXB2 protease (-HIVpinvHXB2) was used as negative control. As shown in Fig. 1 , recombinant phages encoding single mutant proteases displayed growth efficiency that ranges from 0.05-to 0.95-fold of the WT -HIVpHXB2 growth. Importantly, the presence of different point mutations resulted in different degrees of protease activity. Phages encoding the amino acid substitutions M46L and I84V were the only single-mutant protease phages that replicated similarly to the WT -HIVpHXB2 phage. Accordingly, the growth titers for -HIVpM46L and -HIVpI84V (2900 Ϯ 700 and 2700 Ϯ 700 PFU/l, respectively) were not statistically different (P ϭ 0.63 and P ϭ 0.26, respectively) from that obtained with the WT -HIVpHXB2 (3000 Ϯ 1100 PFU/l). The phage encoding the amino acid substitutions D30N replicated up to 20 times less efficiently than the WT -HIVpHXB2 phage, displaying the lowest growth efficiency (150 Ϯ 80 PFU/ l) of all single mutants analyzed in this study. Phages encoding the amino acid substitutions G48V, I50V, or L90M were also less efficient than WT -HIVpHXB2 phage, showing growth titers of 1300 Ϯ 600, 1100 Ϯ 300, and 1100 Ϯ 500 PFU/l, respectively. Nevertheless, the catalytic efficiency of the G48V, I50V, and L90M single mutants were much higher (8-fold) than that observed with the phage encoding the D30N substitution (P Ͻ 0.001), but lower (0.4-fold) than that observed with the WT HIV-1 protease (P Ͻ 0.001). The phage encoding the amino acid substitution V82A replicated more effi-
Comparative growth of phages containing the HIV-1 protease single mutants in cells expressing the cI.HIV-1-cro construct. The growth of phages encoding a single protease substitution (gray bars) was compared to the growth of WT -HIVpHXB2 (black bar). The growth of a phage encoding an inverted HXB2 protease -HIVpinvHXB2 is also included (white bar). Average values and standard deviation are illustrated. Each data point is the average of 13 to 38 independent experiments, depending on specific phage. ciently than -HIVpD30N, but less efficiently than -HIVpG48V, -HIVpI50V, or -HIVpL90M ( Fig. 1) . Thus, -HIVpV82A growth titer (600 Ϯ 300 PFU/l) was statistically different from that obtained with phages encoding the substitutions G48V, I50V, or L90M (P Ͻ 0.001). In brief, we have found that the seven single mutant proteases tested could be grouped in four different levels of catalytic activity. These findings demonstrate that quantitation of the protease activity with the bacteriophage lambda-based genetic screen system makes it possible to monitor a wide range of different proteolytic activities. Furthermore, as -HIVpD30N is a catalytically compromised mutant, the system is sensitive enough to characterize proteases of low catalytic activity.
Effect of single substitutions on resistance to PIs
Seven point substitutions have been designated as primary resistance mutation due to its critical role in conferring drug resistance. The bacteriophage lambdabased genetic screen system was used to assess how the different primary resistance substitutions affect the HIV-1 protease susceptibility to four different PIs: IDV, RTV, SQV, and NFV. For every recombinant phage we evaluated the growth efficiency in the presence of varying concentrations of each PI and calculated the IC 50 against each mutant (see Table 2 and Fig. 2 ). We compared these values with those obtained with the phage encoding the WT HIV-1 protease (-HIVpHXB2). None of the single mutant phages displayed a high level of drug resistance. The phage encoding the I84V substitution showed the highest and widest level of resistance, being 10-fold more resistant to IDV than WT -HIVpHXB2 and cross-resistant to SQV (9-fold) and RTV (8-fold) (Fig. 2) . The phage encoding the substitution G48V was clearly less sensitive to SQV (sevenfold) and IDV (fourfold) than WT -HIVpHXB2, but not to RTV and NFV. The mutant M46L displayed a greater resistance to RTV (fivefold) and IDV (threefold) than WT -HIVpHXB2. In contrast, the phage encoding the substitution D30N was only slightly more resistant to NFV (threefold) than WT -HIVpHXB2. Interestingly, this phage encoding the substitution D30N appeared to be more susceptible to RTV (15-fold) than WT -HIVpHXB2 (Fig. 2B ). Resistance to amprenavir is characterized by the appearance of the I50V substitution. As expected, the phage encoding the substitution I50V did not display a significant increase in resistance to SQV, RTV, IDV, and NFV. Substitution at position 82, which is primarily associated with IDV and RTV resistance, showed a decrease of susceptibility (seven-and threefold, respectively) to both drugs. Finally, the phage en- coding the L90M substitution was resistant to RTV (fivefold) and slightly less sensitive to NFV (twofold) than WT -HIVpHXB2.
Taken together, these results indicated that the presence of single primary resistance mutations decreased the HIV-1 protease drug susceptibility, but never reached a level of resistance as high as we previously described for phages encoding multiple mutated proteases . In addition, similar to that found when the proteolytic activities of these mutants were analyzed, a wide range of different drug susceptibilities was found, demonstrating that this system can reproducibly distinguish small differences in PI susceptibilities.
DISCUSSION
Despite the complex pattern of mutations related to PI resistance, it has been previously demonstrated that some of them play a major role in conferring drug resistance. Primary resistance mutations are the first mutations selected in PI-treated patients Nijhuis et al., 1999) . Primary resistance mutations generally decrease inhibitor binding to the enzyme and are considered critical in the development of drug resistance . Within the HIV-1 protease gene, the seven amino acid changes D30N, M46L, G48V, I50V, V82A, I84V, and L90M analyzed in this study correspond to primary resistance mutations for the inhibitors RTV, SQV, IDV, NFV, and amprenavir. In a previous article, we described a simple genetic screen system to evaluate the activity and phenotype of the HIV-1 protease . Here, we tested if this genetic assay could be used to characterize HIV-1 protease single variants. We demonstrate that HIV-1 protease primary resistance mutations modify the activity and phenotype of the enzyme. Importantly, different protease single mutants displayed different catalytic efficiencies and different PI resistance profiles.
Except for amino acid changes M46L and I84V, the introduction of one primary resistance mutation in the protease gene resulted in a significant reduction of the catalytic efficiency of -HIV-1ps (Fig. 1) . All but amino acid 46 and 90 are located in the substrate-binding cleft of the enzyme (Boden and Markowitz, 1998) . Thus, primary resistance mutations generally decrease inhibitor binding to the enzyme, allowing the virus to grow in a drug-containing medium (Maschera et al., 1996; Schock et al., 1996) . Moreover, these mutations impair the replication capability of the virus (Mammano et al., 2000; Nijhuis et al., 1999) . For this reason, complex genotypic patterns are observed in vivo, probably reflecting the interplay of multiple substitutions to reach equilibrium between drug resistance and proteolytic activity. Our analysis confirms that the presence of one primary resistance mutation generally resulted in a worse catalytic efficiency of the enzyme, but none originated a nonfunc-tional protein (Fig. 1 ). Interestingly, we are able to quantify the catalytic defect of these enzymes and to distinguish various degrees of proteolytic activity. Accordingly, specific growth values of phages encoding single mutant proteases were 1-to 20-fold lower than the WT enzyme, depending on the modified position. These results demonstrate that the genetic screen system used here was reproducible and sensitive enough to allow the quantification of a wide range of different proteolytic activities. Overall, our results are in agreement with previous studies in which protease primary mutations were introduced on purified proteases (Gulnik et al., 1995; Shao et al., 1997) or HIV-1 infectious clones. Thus, the low proteolytic activity observed in this study with the D30N mutant supports the ex vivo decreased replicative capacity of a virus clone encoding this single substitution (Martinez-Picado et al., 1999) . Moreover, in the former study the D30N mutant was also the least fit of the HIV-1 mutants compared. The single mutation G48V also affected the growth efficiency of the phage encoding this substitution (Fig. 1) , confirming the loss of infectivity of viruses encoding this substitution (Mammano et al., 2000) . Analogous to our results, a loss of infectivity has been observed in viruses encoding the single mutation V82A (Mammano et al., 2000) , while virus clones encoding the single mutations M46L or L90M have been shown to be as infectious as the WT virus (Mammano et al., 2000; Martinez-Picado et al., 2000) .
Genotypic analysis of HIV-1 variants that escape drug pressure has allowed for the identification of multiple amino acid changes consistently related to drug resistance. In fact, we previously demonstrated that phages encoding proteases obtained from patients failing antiretroviral therapy and harboring many resistance mutations were highly resistance to most PIs tested . Now, our results show that primary resistance mutations, despite a decreased proteolytic activity, increased IC 50 values for RTV, SQV, IDV, and NFV (Table  2 and Fig. 2) , although none of the seven mutations analyzed confer the high level of resistance conferred by multiple mutated HIV-1 proteases. An interesting result of the present study has been the finding that the phage encoding the substitution D30N was more susceptible to RTV (15-fold) than WT -HIVpHXB2 (Fig. 2B ). This result may imply that this mutation may improve posterior therapy with RTV. Importantly, patients failing NFV therapy who have accumulated the D30N mutation conserved a good response to RTV and SQV therapy Tebas et al., 1999; Zolopa et al., 1999) . Furthermore, hypersusceptibility to ritonavir has been observed in viruses, obtained from treated patients, with the D30N mutation (Obry et al., 2002) .
The high level of specificity of the genetic system used here in which modest differences in catalytic efficiency can be quantified should be useful for the characterization of an in vitro generated library of mutated -HIV-1ps.
Using this system, a rapid selection of novel PI-resistant mutants system has been recently reported (Sices et al., 2001) . Coupling random sequences with positive genetic selection will allow the study of functional mutants, which are unlikely to be readily isolated from HIV-1infected patients. Protease mutants may be of interest in the characterization of the catalytic properties of the enzyme in the absence or presence of drugs (M. Cabana and M. A. Martínez, unpublished results) . The lambdabased genetic screening assay differs from current ex vivo methods for detection of phenotypic resistance to HIV-1 protease inhibitors in that it needs M concentrations of drug (Table 2) to inhibit 50% of phage-replicative events (IC 50 ), whereas the IC 50 values calculated with the ex vivo assays are in the nM range for the four protease inhibitors tested . However, previous results obtained either with phages carrying wildtype or with mutated proteases demonstrated that this genetic screening assay can be used to monitor HIV-1 protease inhibition at M concentrations of drug . PI resistance is a result of the stepwise accumulation of amino acids substitutions in the HIV-1 protease as well as in the different cleavage sites of gag and gag-pol, which are substrates for the viral protease. Characterization of the enzymatic activity of mutants conferring PI resistance may be clinically relevant since some PI-resistant HIV-1 replicate less efficiently and can contribute to the preservation of CD4 ϩ cells (Bleiber et al., 2001; Stoddart et al., 2001) . We have validated here a simple genetic screen system which can be a useful tool in the analysis of the contribution of individual mutations on the protease-coding region as well as in the gag and gag-pol cleavage sites during the complex process of PI resistance.
MATERIALS AND METHODS
Construction of HIV-1 protease single mutants
HIV-1 protease single mutants D30N, M46L, G48V, I50V, V82A, I84V, and L90M were constructed by sitedirected mutagenesis using a recombinant PCR protocol (Rashtchian et al., 1992) . A 486-bp fragment (HXB2 positions 2117 to 2603) was PCR amplified from HXB2-infected cell DNA in two fragments, one 5Ј-and one 3Ј-PCR product. For the amplification of the 5Ј fragment the UDGECOL primer (sense) ( Table 1) was used together with an antisense primer containing the desired mutation. For the amplification of the 3Ј fragment the UDGE-COR (antisense) primer (Table 1) was employed together with a sense primer containing the desired mutation. The positive-strand (sense) and negative-strand (antisense) primers used in the mutagenesis procedure are listed in Table 1 . The PCR mixture contained 20 pmol of each primer, 200 M deoxynucleoside triphosphate, 2.5 mM MgCl 2 , PCR buffer [10 mM Tris-HCl (pH 8.3), 50 mM KCl] and 0.5 U AmpliTaq Gold DNA Polymerase (Applied Biosystems) in total reaction volume of 100 l. Cycling parameters were one cycle of denaturation at 95°C for 10 min and then 35 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 30 s and extension at 72°C for 30 s. This was followed by a 7-min incubation at 72°C. 5Ј-and 3Ј-PCR products were mixed with pAMP1 vector DNA (Clone-Amp pAMP System, Gibco-BRL) and digested with uracil DNA glycosilase (Gibco-BRL) for 20 min at 37°C followed by 10 min at 68°C. E. coli XL-1 Blue electrocompetent cells were then transformed and screened for white colonies on ampicillin-IPTG-X-GaL plates. A small-scale plasmid preparation was carried out to recover bacterial DNA.
Construction of recombinant phages
Plasmid preparations were digested with EcoRI, ligated to EcoRI-digested bacteriophage lambda ZapII (Stratagene), and packaged in vitro. Phage stocks were prepared from the correct insert orientation. Phage DNA sequencing confirmed the presence of the desired mutation.
Determination of proteolytic activity and PIs susceptibility
E. coli JM109 cells containing the plasmid p2X-cI.HIV were transformed with plasmid pcI.HIV-cro as previously described . The resulting cells were grown in the presence of 0.2% maltose, harvested by centrifugation, and suspended to 2.0 OD 600 per ml in 10 mM MgSO 4 . Cells (200 l) were infected with 5 ϫ 10 7 PFU of phages containing the different HIV-1 proteases (-HIV-1p). After 15 min at 37°C, the cells were washed with 1 ml of 10 mM MgSO 4 , harvested by centrifugation, and suspended in 1 ml of LB medium containing 12.5 g tetracycline, 0.2% maltose, 10 mM MgSO 4 , 0.1 mM IPTG, and the appropriate drug concentration (see Table 2 ). The cell cultures were incubated at 37°C for 3 h and harvested by centrifugation. An additional cycle of selective growth was done by suspending the infected cells with a fresh aliquot (200 l) of JM109 pcI.HIV-cro cells. After two selective growth cycles the titer of the resulting phage was determined by coplating the cultures with 200 l E. coli XL-1 Blue cells (OD 600 ϭ 2.0/ml in per in 10 mM MgSO 4 ) on LB plates using 3 ml top agar containing 12.5 g of tetracycline per ml, 0.2% maltose, 0.1 mM IPTG, and the indicated drug concentration (see Table 2 ). After incubation at 37°C for 6 h, the plaques were counted for growth scores.
Protease inhibitors
Indinavir (IND), ritonavir, saquinavir, and nelfinavir were obtained from Merck & Co. (West Point, PA), Abbot Laboratories (Park Road, IL), Roche Laboratories (London, U.K.), and Agouron Pharmaceuticals (San Diego, CA), respectively.
Statistical analyses
Statistical significance of the difference on selective growth between phages encoding different HIV-1 proteases was established by a nonparametric statistical treatment (Mann-Whitney U test) included in the SPSS version 9.0.1 software package (SPSS Inc.).
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